Publications by Svein Ivar Johannessen
130 publications found
Original articles
Pharmacokinetic Variability of Sulthiame: The Impact of Age, Drug-Drug Interactions, and Biochemical Markers of Toxicity in Patients with Epilepsy
Ther Drug Monit, 46 (2), 237-245
DOI 10.1097/FTD.0000000000001146, PubMed 38158595
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development
Epilepsia, 63 (11), 2883-2910
DOI 10.1111/epi.17376, PubMed 35950617
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development
Epilepsia, 63 (11), 2865-2882
DOI 10.1111/epi.17373, PubMed 35946083
Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy
Epilepsy Res, 183, 106946
DOI 10.1016/j.eplepsyres.2022.106946, PubMed 35609355
Changes in the use of antiseizure medications in children and adolescents in Norway, 2009-2018
Epilepsy Res, 181, 106872
DOI 10.1016/j.eplepsyres.2022.106872, PubMed 35180640
Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation
Epileptic Disord, 23 (2), 426-431
DOI 10.1684/epd.2021.1273, PubMed 33935028
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development
Epilepsia, 61 (11), 2340-2364
DOI 10.1111/epi.16725, PubMed 33190243
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development
Epilepsia, 61 (11), 2365-2385
DOI 10.1111/epi.16726, PubMed 33165915
Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome
Ther Drug Monit, 42 (5), 744-753
DOI 10.1097/FTD.0000000000000781, PubMed 32558674
Clinical experience combined with therapeutic drug monitoring of lacosamide
Acta Neurol Scand, 141 (4), 279-286
DOI 10.1111/ane.13206, PubMed 31853958
Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy
Epilepsy Behav, 98 (Pt A), 110-116
DOI 10.1016/j.yebeh.2019.05.021, PubMed 31330379
Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway
Ther Drug Monit, 41 (3), 340-347
DOI 10.1097/FTD.0000000000000599, PubMed 30688870
Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy
Epilepsy Res, 155, 106148
DOI 10.1016/j.eplepsyres.2019.05.016, PubMed 31195184
Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation
Eur J Clin Pharmacol, 75 (8), 1153-1160
DOI 10.1007/s00228-019-02678-1, PubMed 31001654
Therapeutic drug monitoring of gabapentin in various indications
Acta Neurol Scand, 139 (5), 446-454
DOI 10.1111/ane.13075, PubMed 30710348
Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring
Epilepsy Res, 141, 31-37
DOI 10.1016/j.eplepsyres.2018.02.004, PubMed 29453075
Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines
Drug Des Devel Ther, 12, 271-280
DOI 10.2147/DDDT.S154388, PubMed 29467570
Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015
Epilepsy Res, 139, 35-42
DOI 10.1016/j.eplepsyres.2017.11.001, PubMed 29175562
Pharmacokinetic variability of valproate in women of childbearing age
Epilepsia, 58 (10), e142-e146
DOI 10.1111/epi.13872, PubMed 28833045
Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability
Neurochem Res, 42 (7), 2077-2083
DOI 10.1007/s11064-017-2234-8, PubMed 28349359
Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome
Epilepsy Res, 129, 125-131
DOI 10.1016/j.eplepsyres.2016.12.001, PubMed 28043062
Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring
Epileptic Disord, 18 (4), 367-383
DOI 10.1684/epd.2016.0880, PubMed 27965183
The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice
Ther Drug Monit, 38 (4), 499-505
DOI 10.1097/FTD.0000000000000306, PubMed 27414974
Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications
Eur J Clin Pharmacol, 72 (10), 1245-1254
DOI 10.1007/s00228-016-2092-3, PubMed 27411937
Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability
Ther Drug Monit, 38 (3), 350-7
DOI 10.1097/FTD.0000000000000272, PubMed 26751267
Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs
Acta Neurol Scand, 135 (1), 80-87
DOI 10.1111/ane.12578, PubMed 26923477
Availability of antiepileptic drugs across Europe
Epilepsia, 56 (12), e191-7
DOI 10.1111/epi.13210, PubMed 26477534
Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice
Seizure, 28, 88-91
DOI 10.1016/j.seizure.2015.02.017, PubMed 25758302
Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis
Mult Scler Int, 2015, 317859
DOI 10.1155/2015/317859, PubMed 26221541
Probable topiramate-induced diarrhea in a 2-month-old breast-fed child - A case report
Epilepsy Behav Case Rep, 2, 22-3
DOI 10.1016/j.ebcr.2013.12.006, PubMed 25667861
Withdrawal of antiepileptic drugs during presurgical video-EEG monitoring: an observational study for evaluation of current practice at a referral center for epilepsy
Acta Neurol Scand, 129 (4), 243-51
DOI 10.1111/ane.12179, PubMed 23980664
Pharmacological treatment of psychiatric comorbidity in patients with refractory epilepsy
Epilepsy Behav, 29 (1), 77-81
DOI 10.1016/j.yebeh.2013.06.031, PubMed 23939032
Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication
Ther Drug Monit, 34 (4), 440-5
DOI 10.1097/FTD.0b013e31825ee389, PubMed 22777154
Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population
Epilepsy Res, 95 (1-2), 51-9
DOI 10.1016/j.eplepsyres.2011.02.012, PubMed 21435840
Antiepileptic drug interactions - principles and clinical implications
Curr Neuropharmacol, 8 (3), 254-67
DOI 10.2174/157015910792246254, PubMed 21358975
Psychiatric comorbidity in patients with epilepsy: a population-based study
Eur J Clin Pharmacol, 66 (11), 1151-60
DOI 10.1007/s00228-010-0861-y, PubMed 20669014
Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions
Epilepsy Res, 87 (1), 31-9
DOI 10.1016/j.eplepsyres.2009.07.005, PubMed 19679449
Antiepileptic drug treatment of children at a referral centre for epilepsy--does admission make a difference?
Seizure, 18 (8), 573-9
DOI 10.1016/j.seizure.2009.05.011, PubMed 19576793
Serum concentration/dose ratio of topiramate during pregnancy
Epilepsia, 50 (3), 480-5
DOI 10.1111/j.1528-1167.2008.01776.x, PubMed 19178558
Modifications of antiepileptic drugs for improved tolerability and efficacy
Perspect Medicin Chem, 2, 21-39
PubMed 19787095
Pharmacological Management of Epilepsy Recent Advances and Future Prospects
Drugs, 68 (14), 1925-1939
Clinical use of antiepileptic drugs at a referral centre for epilepsy
Seizure, 16 (4), 356-64
DOI 10.1016/j.seizure.2007.02.006, PubMed 17420145
Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs
Ther Drug Monit, 27 (6), 710-3
DOI 10.1097/01.ftd.0000179852.39717.3e, PubMed 16404799
Levetiracetam concentrations in serum and in breast milk at birth and during lactation
Epilepsia, 46 (5), 775-7
DOI 10.1111/j.1528-1167.2005.54804.x, PubMed 15857447
Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects
Epilepsy Behav, 5 (2), 231-5
DOI 10.1016/j.yebeh.2003.12.005, PubMed 15123025
Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study
Ther Drug Monit, 25 (4), 457-62
DOI 10.1097/00007691-200308000-00007, PubMed 12883229
[Oral contraceptives in women with epilepsy]
Tidsskr Nor Laegeforen, 123 (12), 1674-5
PubMed 12821987
Therapeutic drug monitoring of the newer antiepileptic drugs
Ther Drug Monit, 25 (3), 347-63
DOI 10.1097/00007691-200306000-00016, PubMed 12766564
[Levetiracetam in the treatment of epilepsy]
Tidsskr Nor Laegeforen, 123 (11), 1539-41
PubMed 12822020
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Epileptic Disord, 5 Suppl 1, S17-26
PubMed 12915337
Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data
Epilepsia, 44 (1), 40-5
DOI 10.1046/j.1528-1157.2003.26702.x, PubMed 12581228
A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy
Seizure, 12 (1), 42-6
DOI 10.1016/s1059131102001723, PubMed 12495648
Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment
Epilepsia, 41 (10), 1289-95
DOI 10.1111/j.1528-1157.2000.tb04607.x, PubMed 11051124
[Topiramate--a new antiepileptic agents]
Tidsskr Nor Laegeforen, 120 (13), 1536-8
PubMed 10916475
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
Epilepsy Res, 34 (1), 1-41
DOI 10.1016/s0920-1211(98)00108-9, PubMed 10194110
[Gabapentin--a new antiepileptic agent]
Tidsskr Nor Laegeforen, 118 (6), 872-4
PubMed 9543799
Lidocaine pharmacokinetics and toxicity in newborn pigs
Anesth Analg, 85 (2), 306-12
DOI 10.1097/00000539-199708000-00012, PubMed 9249105
[Serum digitoxin in concomitant use of antiepileptics in routine therapy]
Tidsskr Nor Laegeforen, 117 (14), 2032-5
PubMed 9235681
Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs
Epilepsia, 38 Suppl 1, S18-23
DOI 10.1111/j.1528-1157.1997.tb04512.x, PubMed 9092953
Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference
Epilepsy Res, 22 (3), 235-46
DOI 10.1016/0920-1211(95)00054-2, PubMed 8991791
[Vigabatrin--a new antiepileptic agent]
Tidsskr Nor Laegeforen, 114 (24), 2843-4
PubMed 7998031
[Therapeutic drug monitoring with the help of serum concentration measurements. How are the analytic results distributed in a population?]
Tidsskr Nor Laegeforen, 113 (18), 2242-6
PubMed 8362387
Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn
Pharm Weekbl Sci, 14 (3A), 114-7
DOI 10.1007/BF01962699, PubMed 1502009
Cognitive function and time-of-day variation in serum carbamazepine concentration in epileptic patients treated with monotherapy
Epilepsia, 32 (1), 116-21
DOI 10.1111/j.1528-1157.1991.tb05621.x, PubMed 1985819
[Role of drug assays in the treatment of epileptic patients]
Rev Prat, 40 (4), 319-22
PubMed 2305192
Effect of physical training on aerobic capacity, seizure occurrence, and serum level of antiepileptic drugs in adults with epilepsy
Epilepsia, 31 (1), 88-94
DOI 10.1111/j.1528-1157.1990.tb05365.x, PubMed 2303017
Pharmacokinetics of Anti-epileptic Drugs and their Clinical Significance
Behav Neurol, 3 (1), 1-11
DOI 10.3233/BEN-1990-31S102, PubMed 24487080
Association between regularly occurring complex partial seizures and thyroid function parameters
Epilepsia, 27 (4), 419-22
DOI 10.1111/j.1528-1157.1986.tb03561.x, PubMed 3720700
Valproate monotherapy
Epilepsia, 25 Suppl 1, S73-7
DOI 10.1111/j.1528-1157.1984.tb05642.x, PubMed 6425051
Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy
Acta Neurol Scand, 65 (5), 504-23
DOI 10.1111/j.1600-0404.1982.tb03106.x, PubMed 6810648
[Carbamazepine (Tegretol) poisoning]
Tidsskr Nor Laegeforen, 102 (6), 382-3
PubMed 7157294
Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy
Acta Neurol Scand, 63 (2), 111-21
DOI 10.1111/j.1600-0404.1981.tb00754.x, PubMed 6782820
Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect
Epilepsia, 21 (6), 655-52
DOI 10.1111/j.1528-1157.1980.tb04319.x, PubMed 6777155
Serum of concentrations of immunoglobulins in patients with epilepsy treated with carbamazepine
Acta Neurol Scand, 61 (4), 260-3
DOI 10.1111/j.1600-0404.1980.tb01491.x, PubMed 6769290
Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril
Acta Neurol Scand, 60 (6), 371-4
DOI 10.1111/j.1600-0404.1979.tb07663.x, PubMed 121513
Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans
Scand J Clin Lab Invest, 38 (8), 731-6
DOI 10.3109/00365517809104880, PubMed 105401
[Neonatal abstinence syndrome in children whose mothers were treated for epilepsy during pregnancy]
Tidsskr Nor Laegeforen, 98 (29), 1435-6
PubMed 705734
Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine
Acta Neurol Scand, 55 (6), 506-12
DOI 10.1111/j.1600-0404.1977.tb07629.x, PubMed 878840
Preliminary observations on valproic acid kinetics in patients with epilepsy
Arzneimittelforschung, 27 (5), 1083-5
PubMed 328018
CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients
Br J Clin Pharmacol, 3 (4), 575-82
DOI 10.1111/j.1365-2125.1976.tb04878.x, PubMed 22216497
[General guidlines for the use of anti-epileptica]
Sykepleien, 62 (1-2), 26
PubMed 1038139
Simultaneous determination of some antiepileptic drugs by gas-liquid chromatography
Epilepsia, 15 (4), 611-7
DOI 10.1111/j.1528-1157.1974.tb04033.x, PubMed 4430306
[General principles for the use of antiepileptic drugs]
Tidsskr Nor Laegeforen, 94 (29), 2018-9
PubMed 4420148
[Antiepileptic drugs--protein binding and interaction]
Tidsskr Nor Laegeforen, 94 (29), 2019-21
PubMed 4421142
One daily dose of diphenylhydantoin for patients with epilepsy
Epilepsia, 15 (3), 317-27
DOI 10.1111/j.1528-1157.1974.tb04011.x, PubMed 4527914
Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy
Epilepsia, 14 (4), 373-9
DOI 10.1111/j.1528-1157.1973.tb03976.x, PubMed 4521093
[Can phenytoin cause hyperglycemia?]
Tidsskr Nor Laegeforen, 93 (33), 2423
PubMed 4776309
[Phenytoin--blood levels and clinical aspects]
Tidsskr Nor Laegeforen, 93 (6), 395-8
PubMed 4698026
The concentration of carbamazepine (Tegretol R) in serum and in cerebrospinal fluid in patients with epilepsy
Acta Neurol Scand Suppl, 51, 445-6
PubMed 4514373
One daily dose of diphenylhydantoin (DPH) to patients with epilepsy
Acta Neurol Scand Suppl, 51, 499-500
PubMed 4514392
Review articles
Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring
Epileptic Disord, 25 (4), 454-471
DOI 10.1002/epd2.20069, PubMed 37259844
The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results
Epilepsia, 62 (4), 857-873
DOI 10.1111/epi.16849, PubMed 33638459
A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
Epilepsia Open, 5 (3), 432-441
DOI 10.1002/epi4.12413, PubMed 32913951
Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects
Expert Opin Drug Metab Toxicol, 16 (3), 227-238
DOI 10.1080/17425255.2020.1724956, PubMed 32054370
Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development
Epilepsia, 59 (10), 1842-1866
DOI 10.1111/epi.14555, PubMed 30368788
Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development
Epilepsia, 59 (10), 1811-1841
DOI 10.1111/epi.14557, PubMed 30368792
Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)
Epilepsia, 58 (2), 181-221
DOI 10.1111/epi.13634, PubMed 28111749
Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII)
Epilepsy Res, 130, 27-36
DOI 10.1016/j.eplepsyres.2017.01.004, PubMed 28113141
Specific Patient Features Affect Antiepileptic Drug Therapy Decisions: Focus on Gender, Age, and Psychiatric Comorbidities
Curr Pharm Des, 23 (37), 5639-5648
DOI 10.2174/1381612823666170926103631, PubMed 28950817
Proconvulsant effects of antidepressants - What is the current evidence?
Epilepsy Behav, 61, 287-291
DOI 10.1016/j.yebeh.2016.01.029, PubMed 26926001
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
Epilepsy Res, 111, 85-141
DOI 10.1016/j.eplepsyres.2015.01.001, PubMed 25769377
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)
Epilepsy Res, 103 (1), 2-30
DOI 10.1016/j.eplepsyres.2012.10.001, PubMed 23219031
Safety aspects of antiepileptic drugs--focus on pharmacovigilance
Pharmacoepidemiol Drug Saf, 21 (1), 11-20
DOI 10.1002/pds.2269, PubMed 22069221
Host factors affecting antiepileptic drug delivery-pharmacokinetic variability
Adv Drug Deliv Rev, 64 (10), 896-910
DOI 10.1016/j.addr.2011.10.003, PubMed 22063021
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X)
Epilepsy Res, 92 (2-3), 89-124
DOI 10.1016/j.eplepsyres.2010.09.001, PubMed 20970964
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)
Epilepsy Res, 83 (1), 1-43
DOI 10.1016/j.eplepsyres.2008.09.005, PubMed 19008076
[Seizure exacerbation caused by antiepileptic drugs]
Tidsskr Nor Laegeforen, 128 (18), 2052-5
PubMed 18846119
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
Epilepsia, 49 (7), 1239-76
DOI 10.1111/j.1528-1167.2008.01561.x, PubMed 18397299
Value of therapeutic drug monitoring in epilepsy
Expert Rev Neurother, 8 (6), 929-39
DOI 10.1586/14737175.8.6.929, PubMed 18505358
Pharmacological management of epilepsy: recent advances and future prospects
Drugs, 68 (14), 1925-39
DOI 10.2165/00003495-200868140-00001, PubMed 18778117
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII)
Epilepsy Res, 73 (1), 1-52
DOI 10.1016/j.eplepsyres.2006.10.008, PubMed 17158031
Management of focal-onset seizures: an update on drug treatment
Drugs, 66 (13), 1701-25
DOI 10.2165/00003495-200666130-00004, PubMed 16978035
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Clin Pharmacokinet, 45 (11), 1061-75
DOI 10.2165/00003088-200645110-00002, PubMed 17048972
Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention
Epilepsy Res, 60 (1), 1-16
DOI 10.1016/j.eplepsyres.2004.05.004, PubMed 15279865
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Epilepsy Res, 61 (1-3), 1-48
DOI 10.1016/j.eplepsyres.2004.07.010, PubMed 15570674
Valproate: past, present, and future
CNS Drug Rev, 9 (2), 199-216
DOI 10.1111/j.1527-3458.2003.tb00249.x, PubMed 12847559
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
Epilepsy Res, 51 (1-2), 31-71
DOI 10.1016/s0920-1211(02)00106-7, PubMed 12350382
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
Epilepsy Res, 43 (1), 11-58
DOI 10.1016/s0920-1211(00)00171-6, PubMed 11137386
[Adverse effects of antiepileptic agents]
Tidsskr Nor Laegeforen, 120 (26), 3163-5
PubMed 11109365
Therapeutic monitoring of the new antiepileptic drugs
Eur J Clin Pharmacol, 55 (10), 697-705
DOI 10.1007/s002280050001, PubMed 10663446
[Epilepsy and pregnancy]
Ugeskr Laeger, 161 (46), 6334-8
PubMed 10611831
[Epilepsy and pregnancy]
Tidsskr Nor Laegeforen, 119 (23), 3437-40
PubMed 10553342
Antiepileptic drugs: pharmacokinetic and clinical aspects
Ther Drug Monit, 3 (1), 17-37
DOI 10.1097/00007691-198109000-00003, PubMed 7015579
Other articles
A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV)
Epilepsy Res, 153, 66-67
DOI 10.1016/j.eplepsyres.2019.03.002, PubMed 30910314
Erratum to: Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-A pharmacoepidemiological study and clinical implications
Eur J Clin Pharmacol, 73 (6), 791-792
DOI 10.1007/s00228-017-2252-0, PubMed 28389679
[Clarification about pregabalin and the Norwegian Prescription Database]
Tidsskr Nor Laegeforen, 131 (8), 800-1
DOI 10.4045/tidsskr.11.0292, PubMed 21556068
[The prescription registry and abuse of pregabalin]
Tidsskr Nor Laegeforen, 131 (3), 223
DOI 10.4045/tidsskr.10.1328, PubMed 21304565
[Therapeutic monitoring of antiepileptic drugs]
Zh Nevrol Psikhiatr Im S S Korsakova, 105 (12), 56-9
PubMed 16447570
New antiepileptic drugs
Ann Clin Biochem, 37 ( Pt 4), 551-3
PubMed 10902877
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference
Epilepsy Res, 25 (3), 299-319
DOI 10.1016/s0920-1211(96)00081-2, PubMed 8956930